Coris BioConcept

Coris BioConcept is a leading expert of rapid in vitro diagnostics of human infectious diseases since 1996. Based in Belgium, the company develops, produces and markets IVD kits for respiratory, gastro-enteric and bloodborne pathogens (bacteria, viruses and parasites) as well as serological assays, mainly based on the immunochromatographic technology (ICT). Anti-Microbial Resistance concern pushed Coris BioConcept to develop a range of assays (RESIST) for rapid detection of antibiotic resistance mechanisms.

Aside of this range, another innovative approach for 3GC detection was recently launched with a front line test: BL-RED. Coris BioConcept is now involved in the development of a new molecular assay to be launched by end of 2021. Coris BioConcept was at the forefront to tackle COVID-19 pandemic by developing a rapid ICT assay for SARS-CoV-2 antigen detection launched in March 2020.
This R&D expertise is ideally suited for “on demand” production of innovative solutions in a rapidly changing world that calls for cutting edge biotechnology
to take us forward into a healthy future.

All Coris BioConcept’s products fulfil the CE marking requirements with an ISO 13485 certification and they are used in more than 80 countries with reliable distributorship networks.